Cargando…

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine

Detalles Bibliográficos
Autores principales:	Ren, X, Wan, Y, Xie, X, Xu, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442040/ http://dx.doi.org/10.1186/1742-4690-9-S2-P8

Ejemplares similares

P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold
por: Totrov, M, et al.
Publicado: (2009)

Skin tattooing as an effective tool for delivering DNA and protein vaccine immunogens
por: Chiu, Y, et al.
Publicado: (2012)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
por: Zhang, C, et al.
Publicado: (2009)

Breadth or conservation score (CS): which is more important for HIV-1 T cell based vaccine immunogen design?
por: Kunwar, P, et al.
Publicado: (2012)

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
por: Smith, Andressa A, et al.
Publicado: (2013)

Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors
por: Zhang, X, et al.
Publicado: (2012)

Viral vector delivery of Env trimer immunogens
por: Parks, CL, et al.
Publicado: (2012)

P12-16. Biochemical and immunological characterization of the plant-derived candidate HIV-1 mucosal vaccine CTB-MPR
por: Matoba, N, et al.
Publicado: (2009)

P17-12. Immunogenicity comparison of dna vaccines encompassing HIV-1 tat, rev, integrase (C-half), vif and nef genes derived from different clades
por: Wan, Y, et al.
Publicado: (2009)

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans?
por: Wahren, B, et al.
Publicado: (2006)

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
por: van Montfort, Thijs, et al.
Publicado: (2011)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design
por: Chen, Y, et al.
Publicado: (2012)

IL-12 plus CTB in intranasal DNA-MVA schemes improved magnitude and quality of both systemic and mucosal HIV cellular immune responses
por: Rodriguez, AM, et al.
Publicado: (2012)

P19-01. Pre-clinical immunogenicity of mosaic Asian AE/B HIV-1 DNA vaccine in mice
por: Sirivichayakul, S, et al.
Publicado: (2009)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

Immunogenicity of a lambda phage-based anti-cancer vaccine targeting HAAH
por: Fuller, Steven, et al.
Publicado: (2013)

Phase I clinical trials of safety and immunogenicity of live cultural influenza vaccine vector-flu
por: Nechaeva, Elena A, et al.
Publicado: (2015)

P02-12. Bupivacaine, a local anaesthetic, enhances immunogenicity of a multiepitopic DNA vaccine containing HIV promiscuous CD4 T cell epitopes
por: Rosa, DS, et al.
Publicado: (2009)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Yeast surface display of HIV Env protein variants for the discovery of novel vaccine immunogens
por: Grimm, S, et al.
Publicado: (2012)

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma
por: Malard, Florent, et al.
Publicado: (2021)

P04-07. Guiding the immune system through complex maturation pathways: a novel multi-immunogen approach for elicitation of broadly neutralizing antibodies
por: Xiao, X, et al.
Publicado: (2009)

A minimal T-cell immunogen designed to cover HIV-1 specificities associated with control is immunogenic in mice and breaks CTL immunodominance
por: Mothe, B, et al.
Publicado: (2012)

Evaluation of immunogenicity of rSeM and use of PAMPs as possible enhancers of the immune response
por: da Rosa, Matheus Costa, et al.
Publicado: (2014)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
por: Borthwick, NJ, et al.
Publicado: (2012)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

P11-18. Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV
por: Gunderson, S, et al.
Publicado: (2009)

Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer
por: Miller, Lance D, et al.
Publicado: (2014)

163. Enhancing the Immunogenicity of a Novel, Low-cost Ebola Vaccine
por: Stampfer, Samuel D, et al.
Publicado: (2020)

P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand
por: Melchers, M, et al.
Publicado: (2009)

Enhanced immunogenicity of a nanoparticle therapeutic cancer vaccine targeting HAAH delivered intradermally using 3M's hollow microstructured transdermal system (hMTS)
por: Fuller, Steven, et al.
Publicado: (2015)

P57. Activation of RIG-I induces immunogenic cell death
por: Bek, S, et al.
Publicado: (2014)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Immunotherapy generates selective pressure for acquisition of immunogenic neoantigens in escape tumors
por: Pan, Jenny H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mnlgluir2rlpjn4dvf64v9c1ir